Dendritic Cell-Based Immunotherapy for Solid Tumors
نویسندگان
چکیده
منابع مشابه
Dendritic Cell Maturation with CpG for Tumor Immunotherapy
Background: Bacterial DNA has immunostimulatory effects on different types of immune cells such as dendritic cells (DCs). Application of DCs as a cellular adjuvant represents a promising approach in the immunotherapy of infectious disease and cancers. Objectives: To investigate the effect of tumor antigen pulsed DCs in the presence of CpG-1826 in treatment of a murine model of cancer. Methods: ...
متن کاملDendritic Cell Immunotherapy, the Next Step in Cancer Treatment
Cancer immunotherapy has gained a lot of interest over the past few years due to the success of immune checkpoint inhibitors in treating cancer (1, 2). Immune checkpoint inhibitors, such as monoclonal antibodies against cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) and programmed death 1 (PD-1), have been shown to increase survival of patients with advanced cancers (1, 2). These in...
متن کاملDendritic Cell-Based Immunotherapy for Myeloid Leukemias
Acute and chronic myeloid leukemia (AML, CML) are hematologic malignancies arising from oncogene-transformed hematopoietic stem/progenitor cells known as leukemia stem cells (LSCs). LSCs are selectively resistant to various forms of therapy including irradiation or cytotoxic drugs. The introduction of tyrosine kinase inhibitors has dramatically improved disease outcome in patients with CML. For...
متن کاملTolerogenic dendritic cell-based immunotherapy
Dendritic cells (DC) are established T-cell immunity inducers [1], and are also being viewed increasingly as T-cell tolerance mediators [2, 3]. Normally, DCs regulate immune homeostasis by maintaining the balance between T cell immunity and tolerance. Thus far, DC-based immunotherapy has been primarily a consideration in the field of cancer therapy (for the treatment of cancers using fully matu...
متن کاملDendritic Cell-Based Immunotherapy for Prostate Cancer
Dendritic cells are unique in their ability to stimulate naive T cells. These investigators have developed a prostate cancer vaccine using autologous dendritic cells as a vehicle to present prostate antigens to T cells in vivo.
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Translational Oncology
سال: 2018
ISSN: 1936-5233
DOI: 10.1016/j.tranon.2018.03.007